Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7996665 | 0.98 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7454565 | 0.84 | P2RX7 (0.54) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2632669 | 0.83 | P2RX7 (0.61) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6077799 | 0.81 | P2RX7 (0.64) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2231066 | 0.81 | P2RX7 (0.59) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11808999 | 0.80 | P2RX7 (0.62) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| Bromide SCHEMBL15753399 | 0.80 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9696312 | 0.79 | ALDH1A1 (0.50) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11621763 | 0.79 | P2RX7 (0.56) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL724087 | 0.79 | P2RX7 (0.65) | P2RX7LMNASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| EP-4405041-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118265691-A | Cyclohexylbeta-hydroxyalkylamines and their medical use | 阿托基公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023046882-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2023-03-30 | — | — | WO | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007002126-A1 | ALKYL SULFONAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | H1-5, CYP3A5, HRH3 | P2RX7 674/4885LMNA 554/4885SMN1; SMN2 2479/4885 |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | NPY5R, NPY1R, NPY4R | P2RX7 103/4885LMNA 3300/4885SMN1; SMN2 1478/4885 |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | P2RX7 4446/4885LMNA 2255/4885SMN1; SMN2 3112/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | P2RX7 4291/4885LMNA 2773/4885SMN1; SMN2 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.